Literature DB >> 7095831

Enrichment by counterpart centrifugal elutriation of human lymphocytes cytotoxic to human tumour cells.

T Yasaka, R J Wells, N M Mantich, L A Boxer, R L Baehner.   

Abstract

The enriched fractions of cytotoxic cells responsible for natural killer (NK) activity against both human sarcoma and neuroblastoma (LA-N2) cell lines were readily obtained by countercurrent centrifugal elutriation (CCE). The NK cells were obtained in the larger lymphocyte fractions (fraction 6 +/- 1), having a mean cell volume of 180 u3. The cytotoxic-enriched fraction contained 51% large lymphocytes having cytoplasmic granules. On the other hand, monocytes were purified to greater than 90% and isolated in another fraction (final fraction) and these cells had the lowest NK activity against both human tumour cell lines. However, compared with the lymphocyte fractions, small and large monocytes displayed greater antibody-dependent cellular cytotoxicity (ADCC) activity against human B erythrocytes. These results indicate that NK found to have activity against both tumour cells lines were larger lymphocytes, not small monocytes. Thus, countercurrent centrifugal elutriation (CCE) can provide a sensitive method to obtain enriched fractions of large lymphocytes contained tumoricidal activity against human sarcoma and neuroblastoma cell lines.

Entities:  

Mesh:

Year:  1982        PMID: 7095831      PMCID: PMC1555328     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  10 in total

1.  A rapid method for the separation of functional lymphoid cell populations of human and animal origin on PVP-silica (Percoll) density gradients.

Authors:  J T Kurnick; L Ostberg; M Stegagno; A K Kimura; A Orn; O Sjöberg
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

Review 2.  Morphological and functional characterization of isolated effector cells responsible for human natural killer activity to fetal fibroblasts and to cultured cell line targets.

Authors:  E Saksela; T Timonen; A Ranki; P Häyry
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

3.  Surface-bound immunoglobulin on lymphocytes from normal and immunodeficient humans.

Authors:  S S Froland; J B Natvig
Journal:  Scand J Immunol       Date:  1972       Impact factor: 3.487

4.  Isolation of functional subsets of human peripheral blood monocytes.

Authors:  D A Norris; R M Morris; R J Sanderson; P F Kohler
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

5.  Isolation of human NK cells by density gradient centrifugation.

Authors:  T Timonen; E Saksela
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

6.  Monocyte-mediated antibody-dependent cellular cytotoxicity: a clinical test of monocyte function.

Authors:  D G Poplack; G D Bonnard; B J Holiman; R M Blaese
Journal:  Blood       Date:  1976-12       Impact factor: 22.113

7.  Functions of human monocyte and lymphocyte subsets obtained by countercurrent centrifugal elutriation: differing functional capacities of human monocyte subsets.

Authors:  T Yasaka; N M Mantich; L A Boxer; R L Baehner
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

8.  Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines.

Authors:  R C Seeger; S A Rayner; A Banerjee; H Chung; W E Laug; H B Neustein; W F Benedict
Journal:  Cancer Res       Date:  1977-05       Impact factor: 12.701

9.  Characteristics of human large granular lymphocytes and relationship to natural killer and K cells.

Authors:  T Timonen; J R Ortaldo; R B Herberman
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

10.  Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells.

Authors:  M Jondal; G Holm; H Wigzell
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

  10 in total
  1 in total

1.  Large-scale preparation of adherent lymphokine-activated killer (A-LAK) cells for adoptive immunotherapy in man.

Authors:  R J Melder; C S Rosenfeld; R B Herberman; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.